Portfolio company
Type6
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Type6 develops kinase inhibitors that stabilise proteins in inactive states to treat cancers for the pharmaceutical and drug development industries.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Type6 Therapeutics
This deep-tech company develops kinase inhibitors for cancer treatment, intercepting enzymes in their inactive states to address drug resistance for patients with aggressive tumours.
KyDo Therapeutics
This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.
KyDo
This biotechnology company develops small molecule inhibitors for the treatment of cancer variants in oncology patients.
Signase
This biotechnology company develops small molecule inhibitors of cell replication pathways to treat cancer patients by inhibiting tumour growth.
CasInvent
This company develops selective casein kinase 1 inhibitors to treat resistant cancers, including leukaemias and solid tumours, for patients with limited treatment options.
TargeGen
This company develops small molecule kinase inhibitors to treat blood disorders and inflammatory diseases for patients with unmet medical needs.
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.
TPTX
This biopharmaceutical company develops small molecule tyrosine kinase inhibitors to treat patients with advanced solid tumours and lung cancer.